Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30393778 | 1.00 | KDM4E (0.49) | KDM4EKMT2AMAPTGAAMAPK1 | |
| SCHEMBL1402749 | 0.85 | KDM4E (0.49) | KDM4EKMT2AMAPTGAAMAPK1 | |
| SCHEMBL25015012 | 0.84 | MAPT (0.48) | KDM4EKMT2AMAPTGAAHPGD | |
| SCHEMBL9732329 | 0.83 | HTT (0.48) | KDM4EMAPTGAAMAPK1HSD17B10 | |
| SCHEMBL233846 | 0.83 | APP (0.55) | KDM4EMAPTMAPK1HSD17B10HPGD | |
| SCHEMBL4020950 | 0.83 | IRAK4 (0.42) | KDM4EKMT2AMAPTMAPK1ALDH1A1 | |
| SCHEMBL6467757 | 0.83 | LMNA (0.50) | KMT2AMAPTGAATSHRALDH1A1 | |
| SCHEMBL232890 | 0.83 | CA12 (0.45) | KDM4EMAPTMAPK1HSD17B10HPGD | |
| SCHEMBL31585831 | 0.82 | CA12 (0.50) | KDM4EMAPTGAAHSD17B10TSHR | |
| SCHEMBL15326189 | 0.82 | CA12 (0.50) | KDM4EMAPTGAAHSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMA INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250268903-A1 | RXFP1 AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2025-08-28 | — | — | US | disclosed |
| US-20250221966-A1 | RXFP1 AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2025-07-10 | — | — | US | disclosed |
| US-20250100960-A1 | NAPHTHALENE AND QUINOLINE ANALOGS AS RXFP1 AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2025-03-27 | — | — | US | disclosed |
| US-20250066344-A1 | BENZOTHIAZOLE, BENZOISOXAZOLE, AND BENZODIOXOLE ANALOGS AS RXFP1 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2025-02-27 | — | — | US | disclosed |
| CN-119118880-A | F-18 marked PSMA inhibitor and preparation method and application thereof | 四川大学华西医院 | 2024-12-13 | — | — | CN | disclosed |
| US-12139475-B2 | 2-oxindole compounds | CHEMOCENTRYX, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| CN-118843613-A | RXFP1 agonists | 百时美施贵宝公司 | 2024-10-25 | — | — | CN | disclosed |
| EP-4448504-A1 | NAPHTHALENE AND QUINOLINE ANALOGS AS RXFP1 AGONISTS | Bristol-Myers Squibb Company (US) | 2024-10-23 | — | — | EP | disclosed |
| US-20240336618-A1 | PI4KIIIBETA INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-10-10 | — | — | US | disclosed |
| US-20040152140-A1 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | THE SCRIPPS RESEARCH INSTITUTE | 2004-08-05 | — | — | US | disclosed |
| WO-2004056315-A2 | COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | THE SCRIPPS RESEARCH INSTITUTE (US) | 2004-07-08 | — | — | WO | disclosed |
| US-20040092754-A1 | Derivatives of 4-(trifluoromethyl)-phenol and 4-(trifluoromethylphenyl)-2-(tetrahydropyranyl) ether and method for producing the same | BASF AKTIENGESELLSCHAFT (DE) | 2004-05-13 | — | — | US | disclosed |
| US-20040082779-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-6710056-B2 | PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF HAVE AN EXCELLENT ANTAGONISTIC EFFECT AGAINST ACTIVATED BLOOD COAGULATION FACTOR VII. | AJINOMOTO CO., INC. (JP) | 2004-03-23 | — | — | US | disclosed |
| US-20030109547-A1 | Amidinophenylpyruvic acid derivatives | AJINOMOTO CO. INC (JP) | 2003-06-12 | — | — | US | disclosed |
| EP-1236712-A1 | AMIDINOPHENYLPYRUVIC ACID DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2002-09-04 | — | — | EP | disclosed |
| CN-1261906-A | Alkyl, alkenyl and alkynyl chrysamine G derivatives for the antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition | UNIV PITTSBURGH (US) | 2000-08-02 | — | — | CN | disclosed |
| US-5739336-A | SELECTIVE 5-HYDROXYTRYPTAMINE-2C RECEPTOR ANTAGONISTS | SYNTEX (U.S.A.) INC. (US) | 1998-04-14 | — | — | US | disclosed |
| WO-1997000872-A1 | 1,3,8-TRIAZA- AND 3,8-DIAZA-1-OXASPIRO(4,5)DECANE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 1997-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C9, SSB, C1S | KDM4E 4324/4885KMT2A 4590/4885MAPT 1355/4885 |
| US-20030109547-A1 | Amidinophenylpyruvic acid derivatives | HABP2, F2, F7 | KDM4E 2614/4885KMT2A 3854/4885MAPT 4059/4885 |
| US-20040092754-A1 | Derivatives of 4-(trifluoromethyl)-phenol and 4-(trifluoromethylphenyl)-2-(tetrahydropyranyl) ether and method for producing the same | EPX, CYP4X1, EPHX2 | KDM4E 144/4885KMT2A 898/4885MAPT 2801/4885 |
| US-20250221966-A1 | RXFP1 AGONISTS | RXFP1, RXFP2, RXFP3 | KDM4E 3426/4885KMT2A 3583/4885MAPT 4739/4885 |
| US-12139475-B2 | 2-oxindole compounds | CCR9, CCR1, CCRL2 | KDM4E 3582/4885KMT2A 3106/4885MAPT 3245/4885 |
| US-20250268903-A1 | RXFP1 AGONISTS | RXFP1, RXFP2, RXFP3 | KDM4E 3426/4885KMT2A 3583/4885MAPT 4739/4885 |
| US-20240336618-A1 | PI4KIIIBETA INHIBITORS | PI4KB, PI4K2B, PI4K2A | KDM4E 692/4885KMT2A 1237/4885MAPT 2958/4885 |
| US-20040082779-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | MC4R, MC5R, MC1R | KDM4E 1327/4885KMT2A 2114/4885MAPT 3962/4885 |
| US-20250100960-A1 | NAPHTHALENE AND QUINOLINE ANALOGS AS RXFP1 AGONISTS | RXFP1, RXFP2, RXFP3 | KDM4E 4320/4885KMT2A 3802/4885MAPT 4733/4885 |
| US-20250066344-A1 | BENZOTHIAZOLE, BENZOISOXAZOLE, AND BENZODIOXOLE ANALOGS AS RXFP1 RECEPTOR AGONISTS | RXFP1, RXFP2, RXFP3 | KDM4E 2968/4885KMT2A 4132/4885MAPT 4598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.